In agreement with our mutational assays, impaired S897 phosphorylation could compromise the tumor-promoting activities of EphA2 in cell growth, migration, invasion and, most importantly, sorafenib sensitivity in resistant cells (HuH-7R) relative to control cells overexpressing wild-type EphA2. Here, EPHA2 is linked to neoplasm.